Company Announcements

Intermediate declaration by the Board of Directors

TESSENDERLO-HAM, Belgium--(BUSINESS WIRE)--Oct. 30, 2025-- Regulatory News:

X-FAB (BOURSE:XFAB):

Highlights Q3 2025:

  • Revenue was USD 228.6 million, up 11% year-on-year (YoY) and up 6% quarter-on-quarter (QoQ)
  • Excluding the impact from revenue recognized over time (IFRS 15), revenue was USD 228.9 million, well above the guided range of USD 215-225 million
  • EBITDA at USD 53.9 million, up 7% YoY and up 4% QoQ
  • EBITDA margin of 23.6%; excluding IFRS 15 impact, EBITDA margin was 24.2%, compared to the guidance of 22.5-25.5%
  • EBIT was USD 23.8 million, down 5% YoY and up 10% QoQ

Outlook:

  • Q4 2025 revenue is expected to come in within the range of USD 215-225 million with an EBITDA margin in the range of 22.5% and 25.5%. This corresponds to a full-year revenue in the range of USD 863-873 million in 2025.
  • The guidance is based on an average exchange rate of 1.17 USD/Euro and does not take into account the impact of IFRS 15.

Revenue breakdown per quarter:

in millions of USD

Q4 2023

Q1 2024

Q2 2024

Q3 2024

Q4 2024

Q1 2025

Q2 2025

Q3 2025

Q3 y-o-y growth

Automotive

151.8

135.6

142.4

146.0

128.6

135.4

143.4

146.9

1%

Industrial

54.3

52.6

34.4

31.5

36.1

39.3

47.2

47.6

51%

Medical

16.4

14.5

13.2

12.1

16.5

13.8

15.1

21.2

74%

Subtotal core business

222.5

202.6

190.1

189.6

181.2

188.6

205.7

215.7

14%

92.8%

92.6%

93.7%

92.9%

92.1%

93.2%

94.2%

94.2%

 

CCC1

17.2

16.0

12.6

14.2

15.1

13.6

12.2

13.3

-7%

Others

0.1

0.1

0.1

0.1

0.5

0.2

0.4

0.0

 

Revenue*

239.8

218.7

202.8

204.0

196.8

202.3

218.3

228.9

12%

Impact from revenue recognized over time

-2.0

-2.6

2.3

2.4

-8.0

1.8

-3.0

-0.3

 

Total revenue

237.7

216.2

205.1

206.4

188.8

204.1

215.3

228.6

11%

1Consumer, Communications & Computer

in millions of USD

Q4 2023

Q1 2024

Q2 2024

Q3 2024

Q4 2024

Q1 2025

Q2 2025

Q3 2025

Q3 y-o-y growth

CMOS

188.4

168.3

166.2

175.0

170.8

173.4

185.1

191.8

10%

Microsystems

27.9

24.1

25.1

21.6

20.2

22.9

25.3

27.5

27%

Silicon carbide

23.5

26.3

11.6

7.4

5.8

6.0

7.9

9.6

30%

Revenue*

239.8

218.7

202.8

204.0

196.8

202.3

218.3

228.9

12%

Impact from revenue recognized over time

-2.0

-2.6

2.3

2.4

-8.0

1.8

-3.0

-0.3

 

Total revenue

237.7

216.2

205.1

206.4

188.8

204.1

215.3

228.6

11%

Business development

In the third quarter of 2025, X-FAB recorded revenues of USD 228.6 million, up 11% year-on-year and up 6% quarter-on-quarter. Excluding the impact from revenue recognized over time, quarterly revenue was USD 228.9 million, which is well above the guidance of USD 215-225 million. Third quarter revenue in X-FAB’s core markets – automotive, industrial, and medical – was at USD 215.7 million*, up 14% year-on-year and up 5% quarter-on-quarter, representing a share of 94%* of total revenue.

Order intake for the third quarter amounted to USD 163.0 million, down 25% year-on-year and down 21% compared to the previous quarter. This is primarily due to continued inventory corrections by automotive customers as well as broader macroeconomic uncertainties resulting from geopolitical tensions and trade disputes. These factors have led to more cautious ordering patterns, while customers also take advantage of shorter cycle times placing orders later than usual and with reduced lead time. As a result, visibility is still restricted.

The backlog for the third quarter came in at USD 346.9 million, compared to USD 412.9 million at the end of the preceding quarter.

In the third quarter, X-FAB generated automotive revenue of USD 146.9 million*, up 1% year-on-year and up 2% quarter-on-quarter. Third quarter industrial revenue was USD 47.6 million*, up 51% year-on-year and 1% sequentially, reflecting the overall recovery of the industrial end market. The gradual recovery of X-FAB’s silicon carbide (SiC) business contributed to this positive evolution. Medical revenue in the third quarter hit a record USD 21.2 million*, up 74% year-on-year and 40% quarter-on-quarter, highlighting the steady growth of X-FAB’s medical business. Third quarter growth was mainly driven by contactless temperature sensors, DNA sequencing, and echography applications.

In the third quarter, CMOS revenue recorded a growth of 10%* year-on-year and 4%* quarter-on-quarter; microsystems revenue was up 27%* year-on-year and 9%* sequentially. X-FAB’s SiC business continued to recover, and revenue grew strongly by 30%* year-on-year and 21%* quarter-on-quarter. The number of SiC wafers produced in the third quarter more than doubled year-on-year. SiC revenue growth is partially diluted by the much higher share of SiC raw wafers being supplied by customers today as compared to a year ago. This results in lower total billing due to less pass-through of substrate costs. The positive trend in the evolution of X-FAB’s SiC business is underpinned by increasing bookings attributable to sustained demand from data center, electric vehicle, and renewable energy applications.

Quarterly prototyping revenue was USD 19.7 million*, down 16% year-on-year and 6% quarter-on-quarter.

Prototyping and production revenue* per quarter and end market:

in millions

of USD

Revenue

Q3 2024

Q4 2024

Q1 2025

Q2 2025

Q3 2025

Automotive

Prototyping

9.3

8.9

4.7

5.1

5.5

Production

136.7

119.7

130.8

138.2

141.4

Industrial

Prototyping

8.2

9.6

8.8

12.1

9.7

Production

23.3

26.5

30.5

35.2

37.9

Medical

Prototyping

3.0

2.3

1.5

1.8

2.8

Production

9.1

14.2

12.3

13.2

18.4

CCC

Prototyping

3.0

2.6

1.1

1.7

1.6

Production

11.3

12.6

12.5

10.5

11.6

Operations update

In September, X-FAB announced the inauguration of its new cleanroom in Malaysia, which will increase the site’s manufacturing capacity from 30,000 to 40,000 wafer starts per month. Production at the new facility is being scaled up progressively, with the full increase in capacity anticipated by the fourth quarter of 2026. The expansion will effectively double the capacity for X-FAB’s popular 180nm BCD-on-SOI technology, which is particularly suited for applications such as smart motor drivers, smart LED drivers, and battery management systems.

The recovery of X-FAB’s silicon carbide business is supported by the existing SiC capacity at its Texas facility. The current installed capacity, combined with additional capacity scheduled to become operational by the end of 2026, will enable X-FAB to more than double its present production run rate without necessitating significant further investment.

Capital expenditures for the third quarter amounted to USD 23.5 million, bringing total capex as of September 30 to USD 178.9 million. The full-year capital expenditure projection remains unchanged at USD 250 million.

Financial update

Third quarter EBITDA was USD 53.9 million with an EBITDA margin of 23.6%. Excluding the impact from revenues recognized over time, the EBITDA margin would have been 24.2%, within the guided range of 22.5-25.5%.

Profitability remains unaffected by exchange rate fluctuations as X-FAB’s business is naturally hedged. At a constant USD/Euro exchange rate of 1.10 as experienced in the previous year’s quarter, the EBITDA margin would have been unchanged at 23.6%.

In the third quarter, X-FAB reported a financial result of USD -5.6 million, primarily comprising an interest result of USD -4.3 million. Unrealized foreign exchange losses arising from the revaluation of Euro-denominated debt amounted to USD 0.8 million (non-cash).

Cash and cash equivalents at the end of the third quarter amounted to USD 174.2 million, up 16.5 million compared to the previous quarter, while net debt decreased by USD 21.1 million quarter-on-quarter.

Management comments

Rudi De Winter, CEO of X-FAB Group, commented: “X-FAB continued to grow in the third quarter, posting a solid increase in revenue for the third consecutive period amid a challenging macroeconomic environment. There is significant interest in our specialty technologies. Our silicon carbide business has made measurable progress, with growing design activity on our latest SiC technology platform. Additionally, our Microsystems division continues to advance with collaborative co-creation projects enhancing our growth pipeline. While visibility continues to be limited, I am confident in X-FAB’s positioning that supports sustained long-term business success.”

X-FAB Quarterly Conference Call

X-FAB’s third quarter results will be discussed in a live conference call/audiocast on Thursday, October 30, 2025, at 6.30 p.m. CET. The conference call will be in English.

Please register here for the audiocast (listen only).

Please register here for the conference call (listen and ask questions).

Financial calendar

February 5, 2026

Publication of Q4 2025 results

March 31, 2026

Publication of Annual Report 2025

April 30, 2026

Publication of Q1 2026 results/

 

Annual Shareholders’ Meeting 2026

About X-FAB

X-FAB is a global foundry group providing a comprehensive set of specialty technologies and design IP to enable its customers to develop world-leading semiconductor products that are manufactured at X-FAB's six wafer fabs located in Malaysia, Germany, France, and the United States. With its expertise in analog/mixed-signal technologies, microsystems/MEMS and silicon carbide (SiC), X-FAB is the development and manufacturing partner for its customers, primarily serving the automotive, industrial and medical end markets. X-FAB has approximately 4,300 employees and has been listed on Euronext Paris since April 2017 (XFAB). For more information, please visit www.xfab.com.

Forward-looking information

This press release may include forward-looking statements. Forward-looking statements are statements regarding or based upon our management’s current intentions, beliefs or expectations relating to, among other things, X-FAB’s future results of operations, financial condition, liquidity, prospects, growth, strategies, or developments in the industry in which we operate. By their nature, forward-looking statements are subject to risks, uncertainties and assumptions that could cause actual results or future events to differ materially from those expressed or implied thereby. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein.

Forward-looking statements contained in this press release regarding trends or current activities should not be taken as a report that such trends or activities will continue in the future. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, unless legally required. You should not place undue reliance on any such forward-looking statements, which speak only as of the date of this press release.

The information contained in this press release is subject to change without notice. No re-report or warranty, express or implied, is made as to the fairness, accuracy, reasonableness, or completeness of the information contained herein and no reliance should be placed on it.

Condensed consolidated statement of profit and loss

in thousands of USD

Quarter

ended
30 Sep 2025

unaudited

Quarter

ended
30 Sep 2024

unaudited

Quarter

ended
30 Jun 2025

unaudited

Nine months

ended
30 Sep 2025

unaudited

Nine months

ended
30 Sep 2024

unaudited

Revenue*

228,884

203,982

218,275

649,491

625,541

Impact from revenue recognized over time

-319

2,384

-2,992

-1,531

2,079

Total revenue

228,565

206,366

215,283

647,961

627,620

Revenues in USD in %

56

56

56

57

59

Revenues in EUR in %

44

44

44

43

41

Cost of sales

-180,281

-155,162

-165,350

-505,107

-481,184

Gross profit

48,284

51,204

49,933

142,853

146,436

Gross profit margin in %

21.1

24.8

23.2

22.0

23.3

 

 

 

 

 

 

Research and development expenses

-12,369

-13,087

-13,458

-36,818

-35,581

Selling expenses

-2,088

-2,177

-2,407

-6,743

-6,857

General and administrative expenses

-12,406

-11,369

-13,393

-37,197

-35,840

Rental income and expenses from investment properties

480

534

785

2,042

2,362

Other income and other expenses

1,887

-147

232

2,456

4,455

Operating profit

23,788

24,957

21,693

66,593

74,976

Finance income

4,143

12,191

19,612

30,249

24,744

Finance costs

-9,774

-10,945

-36,994

-60,452

-26,017

Financial result

-5,631

1,246

-17,382

-30,204

-1,273

 

 

 

 

 

 

Profit before tax

18,157

26,204

4,311

36,390

73,703

Income tax

-1,573

-254

-4,702

-7,995

-4,872

Profit for the period

16,584

25,950

-392

28,395

68,831

 

 

 

 

 

 

Operating profit (EBIT)

23,788

24,957

21,693

66,593

74,976

Depreciation

30,078

25,345

29,896

87,923

74,137

EBITDA

53,866

50,302

51,589

154,516

149,113

EBITDA margin in %

23.6

24.4

24.0

23.8

23.8

 

 

 

 

 

 

Earnings per share

0.13

0.20

0.00

0.22

0.53

Weighted average number of shares

130,631,921

130,631,921

130,631,921

130,631,921

130,631,921

 

 

 

 

 

 

EUR/USD average exchange rate

1.16772

1.09825

1.13337

1.11802

1.08740

 

Amounts in the financial tables provided in this press release are rounded to the nearest thousand except when otherwise indicated, rounding differences may occur.

*excluding impact from revenue recognized over time in accordance with IFRS 15

Condensed consolidated statement of financial position

in thousands of USD

Quarter ended

30 Sep 2025

unaudited

Quarter ended

30 Sep 2024

unaudited

Year ended

31 Dec 2024

audited

ASSETS

 

 

 

Non-current assets

 

 

 

Property, plant, and equipment

1,211,016

1,005,438

1,144,620

Investment properties

7,083

7,478

7,412

Intangible assets

6,501

6,053

6,319

Other non-current assets

29

46

42

Deferred tax assets

64,482

83,277

66,725

Total non-current assets

1,289,111

1,102,293

1,225,118

 

 

 

 

Current assets

 

 

 

Inventories

287,471

284,146

281,765

Contract assets

16,561

26,090

18,092

Trade and other receivables

95,100

91,307

96,648

Other assets

85,949

45,154

69,253

Cash and cash equivalents

174,225

315,917

215,837

Total current assets

659,306

762,613

681,595

 

 

 

 

TOTAL ASSETS

1,948,417

1,864,905

1,906,713

 

 

 

 

EQUITY AND LIABILITIES

 

 

 

Equity

 

 

 

Share capital

432,745

432,745

432,745

Share premium

348,709

348,709

348,709

Retained earnings

270,359

249,557

241,648

Cumulative translation adjustment

580

465

462

Treasury shares

-770

-770

-770

Total equity

1,051,623

1,030,707

1,022,794

 

 

 

 

Non-current liabilities

 

 

 

Non-current loans and borrowings

403,356

333,757

369,616

Other non-current liabilities and provisions

2,690

4,833

4,257

Total non-current liabilities

406,047

338,590

373,873

 

 

 

 

Current liabilities

 

 

 

Trade payables

40,978

48,962

67,658

Current loans and borrowings

63,823

33,492

44,517

Other current liabilities and provisions

385,946

413,155

397,872

Total current liabilities

490,747

495,608

510,046

 

 

 

 

TOTAL EQUITY AND LIABILITIES

1,948,417

1,864,905

1,906,713

Condensed consolidated statement of cash flows

in thousands of USD

Quarter

ended
30 Sep 2025

unaudited

Quarter

ended
30 Sep 2024

unaudited

Quarter

ended
30 Jun 2025

unaudited

Nine months

ended
30 Sep 2025

unaudited

Nine months

ended
30 Sep 2024

unaudited

Income before taxes

18,157

26,204

4,311

36,390

73,703

 

 

 

 

 

 

Reconciliation of income before taxes to cash flow arising from operating activities:

37,235

21,988

52,164

120,348

74,692

Depreciation and amortization, before effect of grants and subsidies

30,078

25,345

29,896

87,923

74,137

Amortization of investment grants and subsidies

-1,601

-924

-1,229

-4,062

-2,221

Interest income and expenses (net)

4,302

2,308

4,316

12,373

2,961

Loss/(gain) on the sale of plant, property, and equipment (net)

-1,403

-312

-55

-1,511

-4,083

Loss/(gain) on the change in fair value of derivatives and financial assets (net)

483

1,144

-4,160

-3,677

1,144

Other non-cash transactions (net)

5,376

-5,573

23,396

29,301

2,754

 

 

 

 

 

 

Changes in working capital:

-1,433

29,732

-25,537

-33,752

36,420

Decrease/(increase) of trade receivables

16,463

17,693

-16,471

1,289

36,156

Decrease/(increase) of other receivables and other assets

-5,240

1,361

-6,646

-5,325

20,191

Decrease/(increase) of inventories

736

-6,559

-6,896

-5,706

-12,113

Decrease/(increase) of contract assets

319

-2,384

2,992

1,531

-2,079

(Decrease)/increase of trade payables

656

-3,323

-1,047

-4,542

-17,898

(Decrease)/increase of other liabilities

-14,367

22,944

2,532

-20,999

12,164

 

 

 

 

 

 

Income taxes (paid)/received

-4,023

914

-337

-5,255

-1,754

 

 

 

 

 

 

Net cash from operating activities

49,936

78,838

30,602

117,730

183,061

 

 

 

 

 

 

Cash flow from investing activities:

 

 

 

 

 

Payments for property, plant, equipment and intangible assets

-23,455

-149,775

-53,726

-178,911

-376,648

Acquisition of subsidiary, net of cash acquired

0

0

0

0

-1,634

Proceeds from sale of property, plant, and equipment

1,467

312

65

1,585

4,123

Interest received

994

2,644

1,022

3,180

9,060

 

 

 

 

 

 

Net cash used in investing activities

-20,993

-146,820

-52,639

-174,146

-365,099

Condensed consolidated statement of cash flows – con’t

in thousands of USD

Quarter

ended
30 Sep 2025

unaudited

Quarter

ended
30 Sep 2024

unaudited

Quarter

ended
30 Jun 2025

unaudited

Nine months

ended
30 Sep 2025

unaudited

Nine months

ended
30 Sep 2024

unaudited

Cash flow from (used in) financing activities:

 

 

 

 

 

Proceeds from loans and borrowings

5,467

78,634

21,668

56,038

171,535

Repayment of loans and borrowings

-6,368

-20,582

-17,469

-44,918

-120,339

Receipts of sale and leaseback arrangements

0

32,766

26,925

30,020

59,234

Payments of lease installments

-4,727

-5,080

-9,131

-18,004

-9,309

Interest paid

-5,851

-4,834

-4,851

-15,519

-13,466

 

 

 

 

 

 

Cash flow from (used in) financing activities

-11,478

80,903

17,142

7,617

87,655

 

 

 

 

 

 

Effect of changes in foreign currency exchange rates on cash balances

-918

12,941

5,334

7,187

4,599

Increase/(decrease) of cash and cash equivalents

17,464

12,921

-4,895

-48,799

-94,383

Cash and cash equivalents at the beginning of the period

157,678

290,054

157,240

215,837

405,701

Cash and cash equivalents at the end of

the period

174,225

315,917

157,678

174,225

315,917

*excluding impact from revenue recognized over time according to IFRS 15

X-FAB Press Contact
Uta Steinbrecher
Investor Relations
X-FAB Silicon Foundries
+49-361-427-6489
uta.steinbrecher@xfab.com

Source: X-FAB Silicon Foundries